Thalassemia Kids' growth under microscope: new study eyes hidden risks
NCT ID NCT07509996
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at children with beta-thalassemia major, a genetic blood disorder requiring lifelong transfusions. Researchers will measure growth and check for risk factors like iron overload that may stunt development. No new treatment is given—just careful observation of 85 children to understand what affects their growth.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify key risk factors for growth problems in children with thalassemia, pointing toward better monitoring or supportive care strategies.
- What could go wrong
- This is an observational study with no treatment being tested, so it cannot directly improve outcomes. Results may not apply to other hospitals or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 85 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All children with transfusion-dependent beta-thalassemia major attending the AUCH Hematology Unit will be screened for eligibility.
- Ages
-
12 months to 18 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children aged 1 to 18 years diagnosed with β-thalassemia major based on hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). * Receiving regular blood transfusions as part of standard management at AUCH. * Attending the hematology unit for at least one year prior to enrollment. Exclusion Criteria: * • Children with other types of thalassemia. * Presence of congenital diseases, chronic illnesses other than thalassemia (e.g., malignancy, tuberculosis, chronic hepatitis, congenital heart disease, chronic renal failure, epilepsy, diabetes mellitus), or primary endocrinopathies. * Patients with other causes of short stature, such as hereditary bone dysplasia or systemic disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thalassemia majors (beta-thalassemia major) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.